Venture Capital

 

Life Science; Startups; Venture Capital
November 08, 2010 Posted by
Venture capitalists and startup company executives who attended the latest Silicon Valley Bank SVB Showcase event were generally upbeat about prospects for  technology, life science and cleantech innovation and investment. The quarterly invitation-only pitch event brought together dozens of people from early and growth stage companies seeking to raise their next round of funding, and from venture capitalist firms.
Read More
0 Comments | Join the Discussion

Life Science; Venture Capital
September 03, 2010 Posted by

Have you wondered how many really good life science M&A exits happen every year? Are the big guys even buying? Do these exits actually provide returns that materially affect the venture funds that are investing?

Read More
2 Comments | Join the Discussion

Venture Capital
August 11, 2010 Posted by
SVBanalyzes a portfolio of funds from one of the worst vintages in Venture andfinds a positive return is highly likely.
Read More
0 Comments | Join the Discussion

Venture Capital
May 31, 2010 Posted by
SVB Capital is interested in understanding this issue and the many dynamics necessary for a healthy venture capital industry. Median fund sizes in venture capital have declined dramatically in recent years, and many limited partners have liquidity constraints that have caused them to reduce or pull back from allocations to the asset class.
Read More
0 Comments | Join the Discussion

Venture Capital
March 09, 2010 Posted by
In January 2010, four representatives from the Yangpu District Government of Shanghai arrived in the Bay Area for a three-month educational program at San Francisco State University. While in the Bay Area, they also attended programs with SVB Financial Group. The visit follows Silicon Valley Bank’s addition of a repre
Read More
0 Comments | Join the Discussion

Life Science; Venture Capital
February 04, 2010 Posted by

Silicon Valley Bank’s Michael Hanewich, head of life sciences on the East Coast, leads an hour long conversation between entrepreneur John Mendlein, chairman of Fate Therapeutics and former CEO of Adnexus (acquired by Bristol Myers Squibb in 2007 for more

Read More
0 Comments | Join the Discussion

Venture Capital
October 13, 2009
Since the early days of Genentech and Apple, the venture capital ecosystem has been a vital contributor to and enabler of economic growth in the United States.
Read More

Venture Capital
July 07, 2009
Israel has proven to be one of the centers for technological innovation.
Read More

Venture Capital
June 09, 2009
Israel has proven to be one of the centers for technological innovation.
Read More

Venture Capital
May 12, 2009
In an era of financial challenges and outright fraud, limited partners (LPs) in private equity are taking more care in their investment decisions to understand the changing dynamics for venture-backed companies and the funds that invest in them.
Read More